Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.

L T Zane, S Chanda, K Jarnagin, D B Nelson, L Spelman, Lf Stein Gold

DOI: 10.2217/imt-2016-0023

---

• What is this paper about?

  This paper reviews crisaborole, a new topical medication for atopic dermatitis. It is a non-steroid anti-inflammatory treatment that works by blocking an enzyme called PDE4, which is involved in inflammation.

• How did the authors study this?

  This appears to be a review article summarizing early clinical studies of crisaborole. The authors reviewed existing research on crisaborole's effectiveness and safety.

• What populations did the authors study?

  The paper discusses both children and adults with mild to moderate atopic dermatitis. Up to 90% of atopic dermatitis patients have mild to moderate disease.

• What did the authors find?

  Early studies showed that crisaborole was both effective and safe for treating atopic dermatitis. The medication works by reducing inflammation through a different mechanism than existing treatments.

• What conclusions can we draw?

  Crisaborole could be a promising new treatment option for mild to moderate atopic dermatitis that avoids the safety concerns of current treatments. The authors suggest it may be suitable for both short-term and long-term use in managing atopic dermatitis symptoms.